Similar Articles |
|
The Motley Fool December 30, 2003 Tom Taulli |
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed. |
The Motley Fool February 7, 2008 Brian Orelli |
A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work. |
Chemistry World May 10, 2006 Katharine Sanderson |
Leading Lab Suppliers Merge Analytical instrument firm Thermo Electron and chemical manufacturer Fisher Scientific announced a merger, aiming to become the leading provider of laboratory products and services in the health sciences industry. |
The Motley Fool October 26, 2007 Brian Orelli |
This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line. |
The Motley Fool October 26, 2011 Tim Beyers |
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. |
The Motley Fool August 14, 2007 Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
Bio-IT World January 12, 2004 Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen |
The Motley Fool May 2, 2006 Ryan Fuhrmann |
Sigma-Aldrich Surpasses Average Don't be fooled by appearances -- this isn't your typical chemical company. The shares have had a nice run over the past year, from about $55 to around $68.39. Even at current levels, the shares may be worth picking up, since they appear fairly valued. |
The Motley Fool July 26, 2006 Ryan Fuhrmann |
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings. |
Bio-IT World August 2005 Maureen McDonough |
Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways. |
The Motley Fool October 7, 2010 |
DRIP Portfolio Candidate: Becton, Dickinson Profit from your fear of needles by adding this stock to your DRIP portfolio. |
The Motley Fool October 21, 2010 Moser & Hinmon |
DRIP Candidate Winner: Becton, Dickinson In a health-care bloodbath, Becton, Dickinson pounds Walgreen to a pulp. |